2021
DOI: 10.1002/anie.202110702
|View full text |Cite
|
Sign up to set email alerts
|

A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays

Abstract: Coronavirus disease 2019 (COVID-19) manifests with high clinical variability and warrants sensitive and specific assays to analyze immune responses in infected and vaccinated individuals.U sing Single Molecule Arrays( Simoa), we developed an assay to assess antibody neutralization with high sensitivity and multiplexing capabilities based on antibodymediated blockage of the ACE2-spike interaction. The assay does not require live viruses or cells and can be performed in ab iosafety level 2l aboratory within two … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(9 citation statements)
references
References 32 publications
0
9
0
Order By: Relevance
“…12 C). This device was also adapted for COVID-19 detection with LOD of 0.015 ng mL −1 for IgG and 0.099 pg mL −1 for N protein [ [371] , [372] , [373] , [374] ].
Fig.
…”
Section: Luminescence Immunoassays For Covid-19 Poctsmentioning
confidence: 99%
“…12 C). This device was also adapted for COVID-19 detection with LOD of 0.015 ng mL −1 for IgG and 0.099 pg mL −1 for N protein [ [371] , [372] , [373] , [374] ].
Fig.
…”
Section: Luminescence Immunoassays For Covid-19 Poctsmentioning
confidence: 99%
“…By distinguishing the number of fluorescence-positive microwells, subfemtomolar protein targets could be digitally detected. With this system, various types of biomarkers, including miRNAs and virus, were successfully analyzed [ 77 82 ]. Although the Simoa-based strategies can achieve efficient analysis of biomarkers, they subject to the low sample loading and the requirement of special instruments, which hamper their widespread application.…”
Section: Single-entity Counting-based Digital Bioassaysmentioning
confidence: 99%
“…The dSimoa platform achieved attomolar limits of detection for human interleukin under a dropcasting workflow. However, current digital bioaffinity assays, whether dSimoa or Simoa, rely on antibodies, necessitating a competitive format for small-molecule detection. ,,, These approaches suffer from a narrow dynamic concentration due to the restricted antibody microenvironment for antigen competitive reaction . Actually, much fewer single-molecule detection technologies are available for small molecules , compared with those for biomacromolecules such as proteins and nucleic acids.…”
Section: Introductionmentioning
confidence: 99%